Biliary Tract Cancer Fail Is Another Blow for Merck KGaA/GSK's Bintrafusp

Objective Response Rate Too Low For Filing

 
• By Kevin Grogan
  
Merck KGaA Darmstadt
Approval path for Merck KGaa's bintrafusp unclear

More from Clinical Trials

More from R&D